Surgical Intensive Care Unit, The Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China.
Int J Mol Med. 2018 May;41(5):2527-2534. doi: 10.3892/ijmm.2018.3491. Epub 2018 Feb 13.
The aim of the present study was topreliminarily visualize the distribution of humanumbilical cord‑derivedmesenchymal stem cells (hUC‑MSCs) in treating acute lung injury (ALI) using a targeted fluorescent technique. Anovel fluorescent molecule probe was first synthesized via the specific binding of antigen and antibody in vitro to label the hUC‑MSCs. Two groups of mice, comprising a normal saline (NS)+MSC group and lipopolysaccharide (LPS)+MSC group, were subjected to optical imaging. At 4 h following ALI mouse model construction, the labeled hUC‑MSCs were transplanted into the mice in the NS+MSC group and LPS+MSC group by tail vein injection. The mice were sacrificed 30 min, 1 day, 3 days and 7 days following injection of the labeled hUC‑MSCs, and the lungs, heart, spleen, kidneys and liver were removed. The excised lungs, heart, spleen, kidneys and liver were then detected on asmall animal fluorescent imager. The fluorescent results showed that the signal intensity in the lungs of the LPS+MSC group was significantly higher, compared with that of the NS+MSC group at 30 min (3.53±0.06x10‑4, vs. 1.95±0.05x10‑4 scaled counts/sec), 1 day (36.20±0.77x10‑4, vs. 23.45±0.43x10‑4 scaled counts/sec), 3 days (11.83±0.26x10‑4, vs. 5.39±0.10x10‑4 scaled counts/sec), and 7 days (3.14±0.04x10‑4, vs. 0.00±0.00x10‑4 scaled counts/sec; all P<0.05). The fluorescence intensity in the liver of the LPS+MSC group, vs. NS+MSC group was measured at 30 min (0.00±0.00x10‑4, vs. 0.00±0.00x10‑4 scaled counts/sec); 1 day (5.53±0.08x10‑4, vs. 5.44±0.16x10‑4 scaled counts/sec); 3 days (0.00±0.00x10‑4, vs. 8.67±0.05x10‑4 scaled counts/sec); 7 days (0.00±0.00x10‑4, vs. 0.00±0.00x10‑4 scaled counts/sec). The signal intensity of the heart, spleen and kidneys was minimal. In conclusion, the novel targeted fluorescence molecular probe was suitable for tracking the distribution processes of hUC‑MSCs in treating ALI.
本研究旨在采用靶向荧光技术初步观察人脐带间充质干细胞(hUC-MSCs)在治疗急性肺损伤(ALI)中的分布。首先通过体外抗原与抗体的特异性结合合成了一种新型荧光分子探针来标记 hUC-MSCs。将两组小鼠,包括生理盐水(NS)+MSC 组和脂多糖(LPS)+MSC 组,进行光学成像。在构建 ALI 小鼠模型后的 4 小时,通过尾静脉注射将标记的 hUC-MSCs 移植到 NS+MSC 组和 LPS+MSC 组的小鼠体内。在注射标记的 hUC-MSCs 后 30 分钟、1 天、3 天和 7 天,处死小鼠,取出肺、心、脾、肾和肝。然后将切除的肺、心、脾、肾和肝在小动物荧光成像仪上进行检测。荧光结果显示,LPS+MSC 组肺内的信号强度在 30 分钟(3.53±0.06x10-4,与 1.95±0.05x10-4 个标测/秒)、1 天(36.20±0.77x10-4,与 23.45±0.43x10-4 个标测/秒)、3 天(11.83±0.26x10-4,与 5.39±0.10x10-4 个标测/秒)和 7 天(3.14±0.04x10-4,与 0.00±0.00x10-4 个标测/秒)时明显高于 NS+MSC 组(均 P<0.05)。LPS+MSC 组肝内的荧光强度与 NS+MSC 组相比,在 30 分钟(0.00±0.00x10-4,与 0.00±0.00x10-4 个标测/秒)、1 天(5.53±0.08x10-4,与 5.44±0.16x10-4 个标测/秒)、3 天(0.00±0.00x10-4,与 8.67±0.05x10-4 个标测/秒)和 7 天(0.00±0.00x10-4,与 0.00±0.00x10-4 个标测/秒)时测量到。心、脾和肾的信号强度最小。总之,新型靶向荧光分子探针适用于跟踪 hUC-MSCs 在治疗 ALI 中的分布过程。